Trade Inovio Pharmaceuticals
Inovio Pharmaceuticals is an American biotechnology company that focuses on the discovery, development and marketing of synthetic DNA products for the treatment of cancers and infectious diseases. In April 2020, Inofio was among about 100 companies, academic centers or research organizations developing a vaccine to treat people with COVID-19, with more than 170 total vaccine candidates under development (June 2020). Inovio technology is based on the introduction of engineered DNA into cells, where it becomes transferred to flexible and translated into proteins. Proteins coded by DNA provoke an immune response to antigens from cancers and viruses, by stimulating the production of T-cells and antibodies that help recovery. This technology can be "targeted" with specific types of cancer and immune diseases, such as those produced by the virus. At a Meeting of the Task Force on Genetic Viruses at the White House in March 2020, CEO Joseph Kim said that Inofio scientists had designed a candidate for the INO-4800 vaccine for the CORONAvirus COVID-19 in January just three hours after the genetic sequence of the virus was first published.